← Human Trials & Peer-Reviewed Studies
Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp
Plain-language guide to PMID 28730676 (2018): single-blind randomized controlled trial study of Glucagon in 10 men.
Key Facts
- PMID
- 28730676
- Journal
- Diabetes, obesity & metabolism
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Dash S et al. (6 authors)
- DOI
- 10.1111/dom.13069
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Glucagon.
To investigate the specific effects of intranasal glucagon (ING) on plasma glucose, endogenous glucose production (EGP) and lipid concentration.
Who Took Part
According to the abstract, 10 men were involved.
The age groups tagged for this paper are middle-aged adults, men only.
How the Study Was Run
In design terms this was a randomized, single-blind, placebo-controlled, crossover and pilot study.
Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind Glucagon study one party knew the assignments and the other did not.
Some men received a placebo instead of Glucagon, giving a reference point.
Each person switched between Glucagon and the comparison at some point, usually with a gap in between.
The researchers conducted a single-blind, randomized, crossover study at their academic investigation unit.
The main outcome measures were plasma glucose, EGP, free fatty acid (FFA) and triglyceride (TG) concentrations.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Deuterium, Fasting, Fatty Acids, Nonesterified, Glucagon, Gluconeogenesis and Glucose Clamp Technique.
Author keywords: glucose metabolism.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Glucagon in 10 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.